1545 Park Ave
Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA.
Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful therapeutic tools that can be leveraged by partners and fuel our own pipeline of novel medicines.
Our goal is to revolutionize gene editing for the benefit of patients around the world.
30 articles about Metagenomi
Metagenomi announced that it will participate in two upcoming investor conferences.
Metagenomi announced a Series B extension financing round led by Moderna, Leaps by Bayer and several others.
Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Development and Grow Genetic Medicines Pipeline
Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, today announced the close of a Series B extension financing, co-led by Novo Holdings A/S, Catalio Capital Management and SymBiosis, with participation from new and existing investors.
Metagenomi today announced that Brian C. Thomas, Ph.D., Chief Executive Officer and Founder of Metagenomi, will present a company overview at 11:00 a.m. PT on Monday, January 9, 2023 at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA.
Metagenomi Announces Publication of Data in Nature Communications Describing Novel, Ultra-Small Nucleases for Gene Editing
Metagenomi Announces Publication of Data in Nature Communications Describing Novel, Ultra-Small Nucleases for Gene Editing.
Ionis Pharmaceuticals, Inc. and Metagenomi announced that the companies have entered a collaboration that will leverage Ionis' extensive expertise in RNA-targeted therapeutics and Metagenomi's versatile next-generation gene editing systems to pursue a mix of validated and novel genetic targets that have potential to expand therapeutic options for patients.
BioSpace checked in with some of the members of our NextGen Bio Class of 2022 to see what they've done to earn their place on the list - and what's on the horizon.
Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies
Metagenomi announced that it has opened a new, in-house Good Manufacturing Practices facility, based within its 50,000 square foot campus in Emeryville, California.
Metagenomi, a gene editing company with a versatile portfolio of next-generation CRISPR gene editing tools, today announced its participation in the following investor and industry conferences.
Metagenomi, a genetic medicines company with a versatile portfolio of wholly-owned, next-generation gene editing tools, today announced that it was selected as one of this year’s 11 most promising private biotechnology companies by John Carroll, founder and editor of Endpoints News.
Metagenomi, a gene editing company with a versatile portfolio of next-generation CRISPR gene editing tools, announced its participation in the following investor and industry conferences.
The American Society of Gene and Cell Therapy annual meeting continues to see companies showcasing promising therapeutics for multiple disease indications.
Metagenomi Presents New Preclinical Data at ASGCT on Proprietary, Highly Efficient CRISPR Gene Editing Systems and a Novel Family of CRISPR-Associated Transposases (CASTs)
Metagenomi Presents New Preclinical Data at ASGCT on Proprietary, Highly Efficient CRISPR Gene Editing Systems and a Novel Family of CRISPR-Associated Transposases (CASTs).
Metagenomi to Present New Preclinical Data at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Metagenomi today announced that two presentations will be made at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, taking place virtually and in Washington, D.C., May 16-19, 2022.
Metagenomi Presents Findings on Novel Families of Ultra Small, CRISPR Enzymes at the Keystone Symposia Precision Genome Engineering Conference
Metagenomi presented findings on the identification of novel families of compact, programmable enzymes for genome editing at the Keystone Symposia Precision Genome Engineering and Emerging Cellular Therapies Conference, on April 30.
Metagenomi announced that Simon Harnest, Chief Investment Officer and SVP, Strategy of Metagenomi, will participate in a panel at the Longwood Healthcare Leaders Spring Webconference which will be held virtually on Wednesday, May 4, 2022.
Metagenomi, a genetic medicines company with a versatile portfolio of next-generation gene editing tools, announced that it will present at two upcoming investor conferences.
Biopharma and life sciences companies continue to strengthen their executive teams and boards with this week’s Movers & Shakers.
Metagenomi Appoints Christine Foster, Ph.D., as CBO, and Alan H. Cohen, M.D., as CMO & SVP of Monogenic Diseases
Metagenomi today announced the appointment of Christine Foster, PhD, as Chief Business Officer and Alan H. Cohen, MD, as Chief Medical Officer and Senior Vice President of Monogenic Diseases.
Metagenomi announced that Brian C. Thomas, PhD, Founder and CEO of Metagenomi, and Chris Brown, PhD, Senior Director of Discovery, will present at the virtual Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022.